Have a feature idea you'd love to see implemented?
Let us know!
HOOK HOOKIPA Pharma Inc
Price (delayed)
$3.87
Market cap
$46.65M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.32
Enterprise value
-$25.6M
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system.
Highlights
The EPS has soared by 52% YoY and by 13% from the previous quarter
HOOK's net income is up by 29% year-on-year but it is down by 2.3% since the previous quarter
The debt has declined by 19% since the previous quarter but it has increased by 14% year-on-year
The company's equity fell by 23% YoY and by 18% QoQ
HOOKIPA Pharma's gross profit has decreased by 2.6% QoQ
Key stats
What are the main financial stats of HOOK
Market
Valuations
Earnings
Shares outstanding
12.05M
Market cap
$46.65M
Enterprise value
-$25.6M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.44
Price to sales (P/S)
0.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.49
Revenue
$52.16M
EBIT
-$48.33M
EBITDA
-$45.21M
Free cash flow
-$77.48M
Per share
Balance sheet
Liquidity
EPS
-$4.32
Free cash flow per share
-$7.83
Book value per share
$8.7
Revenue per share
$5.27
TBVPS
$12.64
Total assets
$125.05M
Total liabilities
$38.98M
Debt
$4.9M
Equity
$86.06M
Working capital
$79.52M
Debt to equity
0.06
Current ratio
3.86
Quick ratio
3.58
Net debt/EBITDA
1.6
Margins
Efficiency
Dividend
EBITDA margin
-86.7%
Gross margin
100%
Net margin
-93.2%
Operating margin
-124.5%
Return on assets
-32.6%
Return on equity
-51.8%
Return on invested capital
-232.7%
Return on capital employed
-49.7%
Return on sales
-92.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HOOK stock price
How has the HOOKIPA Pharma stock price performed over time
Intraday
-2.76%
1 week
-0.77%
1 month
-15.13%
1 year
-14.95%
YTD
-52.22%
QTD
-10%
Financial performance
How have HOOKIPA Pharma's revenue and profit performed over time
Revenue
$52.16M
Gross profit
$52.16M
Operating income
-$64.92M
Net income
-$48.6M
Gross margin
100%
Net margin
-93.2%
The net margin has surged by 78% year-on-year but it has declined by 5% since the previous quarter
The operating margin has surged by 75% year-on-year but it has declined by 4.3% since the previous quarter
HOOK's net income is up by 29% year-on-year but it is down by 2.3% since the previous quarter
The company's operating income rose by 18% YoY
Growth
What is HOOKIPA Pharma's growth rate over time
Valuation
What is HOOKIPA Pharma stock price valuation
P/E
N/A
P/B
0.44
P/S
0.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.49
The EPS has soared by 52% YoY and by 13% from the previous quarter
The P/B is 65% below the 5-year quarterly average of 1.3 and 34% below the last 4 quarters average of 0.7
The company's equity fell by 23% YoY and by 18% QoQ
The price to sales (P/S) is 91% lower than the 5-year quarterly average of 8.7 and 64% lower than the last 4 quarters average of 2.1
The revenue has decreased by 2.6% QoQ
Efficiency
How efficient is HOOKIPA Pharma business performance
The ROS has soared by 78% YoY but it has contracted by 5% from the previous quarter
The company's return on invested capital rose by 24% YoY and by 12% QoQ
HOOKIPA Pharma's return on equity has increased by 22% YoY but it has decreased by 10% QoQ
The ROA is up by 19% YoY but it is down by 14% from the previous quarter
Dividends
What is HOOK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HOOK.
Financial health
How did HOOKIPA Pharma financials performed over time
The total liabilities has dropped by 51% year-on-year and by 6% since the previous quarter
The total assets has contracted by 35% YoY and by 14% from the previous quarter
The debt is 94% smaller than the equity
HOOKIPA Pharma's debt to equity has surged by 50% YoY
The company's equity fell by 23% YoY and by 18% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.